Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases (Q33293423)

25 July 2017

Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases (English)

1 reference

25 July 2017

1 reference

1 reference

1 reference

4

Robert L Vessella

1 reference

25 July 2017

Colm Morrissey

1

1 reference

25 July 2017

Paul L Kostenuik

series ordinal

2

1 reference

25 July 2017

Lisha G Brown

series ordinal

3

1 reference

25 July 2017

Eva Corey

series ordinal

5

1 reference

25 July 2017

language of work or name

English

0 references

publication date

3 August 2007

1 reference

25 July 2017

1 reference

25 July 2017

7

1 reference

25 July 2017

148

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-7-148

25 July 2017

0 references

cites work

IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Regulation of cancer cell migration and bone metastasis by RANKL.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Denosumab in postmenopausal women with low bone mineral density

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Prostate cancer mediates osteoclastogenesis through two different pathways

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Characterization of C4-2 prostate cancer bone metastases and their response to castration

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

A multigenic program mediating breast cancer metastasis to bone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Osteoprotegerin and rank ligand expression in prostate cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Total and regional bone mass and biochemical markers of bone remodeling in metastatic prostate cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Modifications of the Goldner and Gomori one-step trichrome stains for plastic-embedded thin sections of bone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-148

MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-148

Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-148

Osteoprotegerin in prostate cancer bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-148

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-148

In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-148

Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-148

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-148

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-148

Serum osteoprotegerin levels are increased in patients with advanced prostate cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Technology evaluation: denosumab, Amgen

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034387

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

10 December 2018

1 reference

12 December 2020

Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells

1 reference

12 December 2020

Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone

1 reference

12 December 2020

Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone

1 reference

12 December 2020

Radiotherapy of bone metastases

1 reference

12 December 2020

Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer

1 reference

12 December 2020

Clinical Course of Bone Metastasis from Prostatic Cancer Following Endocrine Therapy: Examination with Bone X-Ray

1 reference

12 December 2020

Bone metabolic markers in bone metastases

1 reference

12 December 2020

Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: an immunohistochemical study

1 reference

12 December 2020

Osteopontin: possible role in prostate cancer progression

1 reference

12 December 2020

Breast cancer cells interact with osteoblasts to support osteoclast formation

1 reference

12 December 2020

The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft

1 reference

12 December 2020

The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone

1 reference

12 December 2020

[Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases]

1 reference

12 December 2020

Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-7-148

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference